Mikulicz disease is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in bringing together a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment plans for and management of Mikulicz disease require individual development, typically including pharmacotherapy, rehabilitation interventions, regular follow-up management, etc. In recent years, with the development of therapeutically oriented, immune-regulatory therapies and precision medicine, many autoimmune and rheumatic immune disorders that have previously been difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changing conditions. Multidisciplinary collaboration (MDT) is particularly important for integrated management of IgG4-related Mikulicz disease. The platform serves the China International Medical Service System, which combines national and international authorities in the field of autoimmunity and rheumatic immunity to provide the following services to patients: 1.
Remote pre-diagnosis: pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: arranging face-to-face diagnostics with authorities, developing personalized treatment plans; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.